"Designing Growth Strategies is in our DNA"

U.S. Alzheimer’s Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonist, Combination Drugs, and Others), By Application (Disease Progression and Symptom Management) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy & Drug Stores, and Online Pharmacy), and Country Forecast, 2023-2030

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI109140

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Alzheimer’s Disease in the U.S., 2022/2023
    2. New Product Launches, By Key Players
    3. Pipeline Analysis, By Key Players
    4. Key Industry Developments (Mergers, Acquisitions, and Partnerships)
    5. Impact of COVID-19 on the Market
  5. U.S. Alzheimer’s Drugs Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonist
      3. Combination Drugs
      4. Others
    2. Market Analysis, Insights and Forecast – By Application
      1. Disease Progression
      2. Symptom Management
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy & Drug Stores
      3. Online Pharmacy
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. EISAI CO., LTD.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      2. Novartis AG
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      3. Biogen Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      4. H. Lundbeck A/S
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      5. Otsuka Pharmaceutical Co., Ltd.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Alzheimer’s Disease in the U.S., 2022/2023
    2. New Product Launches, By Key Players
    3. Pipeline Analysis, By Key Players
    4. Key Industry Developments (Mergers, Acquisitions, and Partnerships)
    5. Impact of COVID-19 on the Market
  5. U.S. Alzheimer’s Drugs Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonist
      3. Combination Drugs
      4. Others
    2. Market Analysis, Insights and Forecast – By Application
      1. Disease Progression
      2. Symptom Management
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy & Drug Stores
      3. Online Pharmacy
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. EISAI CO., LTD.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      2. Novartis AG
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      3. Biogen Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      4. H. Lundbeck A/S
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      5. Otsuka Pharmaceutical Co., Ltd.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
Read Less

Figure 1: U.S. Alzheimer’s Drugs Market Revenue Breakdown (USD billion, %) by Drug Class, 2022 & 2030

Figure 2: U.S. Alzheimer’s Drugs Market Value Share (%), By Drug Class, 2022 & 2030

Figure 3: U.S. Alzheimer’s Drugs Market Value Share (%), By Application, 2022 & 2030

Figure 4: U.S. Alzheimer’s Drugs Market Value Share (%), By Distribution Channel, 2022 & 2030

Figure 5: U.S. Alzheimer’s Drugs Market Share (%), By Company, 2022

Table 1: U.S. Alzheimer’s Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019–2030

Table 2: U.S. Alzheimer’s Drugs Market Revenue (USD billion) Forecast, By Application, 2019–2030

Table 3: U.S. Alzheimer’s Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019–2030

U.S. Alzheimer's Drugs Market
  • 2019-2030
  • 2022
  • 2019-2021
  • 70
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports